Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 635

Sort by

Sort Order Select

Journal Articles

Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation

Danniel Zamora, Elizabeth R. Duke, Hu Xie, Bradley C. Edmison, Brenda Akoto, Richard Kiener, Terry Stevens-Ayers, Ralf Wagner, Marco Mielcarek, Wendy M. Leisenring, Keith R. Jerome, Joshua T. Schiffer, Greg Finak, Stephen C. De Rosa, Michael Boeckh

Blood (2021) 138 (1): 34–43.

https://doi.org/10.1182/blood.2020009396

Published: 2021

Includes: Supplemental data

Journal Articles

How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation

Hermann Einsele, Per Ljungman, Michael Boeckh

Blood (2020) 135 (19): 1619–1629.

https://doi.org/10.1182/blood.2019000956

Published: 2020

Journal Articles

Integrated Immune Signature Analyses Identifies Evolution of Distinct Immunoregulatory Cell Populations Which Control Alloreactivity after Allogeneic HSCT

James Aries, Sarah Charrot, Jennifer Ball, Matthew Mee, Symeon Theocharidis, Sofie Van Gassen, Sameena Iqbal, John G. Gribben, MD DSc, Jeff Davies, MBBS, PhD

Blood (2019) 134 (Supplement_1): 595.

https://doi.org/10.1182/blood-2019-124875

Published: 2019

Journal Articles

Transcriptomic Analysis of CD4+ T Cell Dysfunction during Gvhd: Evidence for Profound Reprograming of T Cell Signaling during Acute Gvhd That Is Controlled during CD28:CD80/86 Costimulation Blockade with Abatacept

Benjamin Watkins, Yvonne Suessmuth, Kayla Betz, BS, Alison Yu, PhD, Brandi Bratrude, Muna Qayed, MD MSc, Kathryn Pellegrini, Steven Bosinger, Amelia Langston, MD, John T. Horan, MDMPH, Bruce R. Blazar, MD, Leslie Kean, MD PhD

Blood (2019) 134 (Supplement_1): 596.

https://doi.org/10.1182/blood-2019-131955

Published: 2019

Journal Articles

Haplo-Cord Transplantation with Anti-Thymocyte Globulin: Comparative Clinical Outcomes with or without Routine G-CSF Administration

Nina Orfali, MB,PhD, Alexandra Gomez-Arteaga, MD, Danielle Guarneri, BS, CCRP, Jingmei Hsu, MD, Adrienne A. Phillips, MD MPH, Usama Gergis, MD MBA, Tsiporah B. Shore, MD, Sebastian A. Mayer, MD, Koen Van Besien, MD PhD

Blood (2019) 134 (Supplement_1): 2000.

https://doi.org/10.1182/blood-2019-129452

Published: 2019

Journal Articles

Post-Transplant Cyclophosphamide in Allogeneic Bone Marrow Transplantation for the Treatment of Benign Hematologic Diseases

Mark Leick, MD, Bradley Hunter, MD MPH, Zachariah Defilipp, MD, Bimalangshu Dey, MD, Areej El-Jawahri, MD, Matthew J. Frigault, MD, Steven L McAfee, MD, Thomas Spitzer, MD, Paul V. O'Donnell, MD PhD, Yi-Bin Chen

Blood (2019) 134 (Supplement_1): 1978.

https://doi.org/10.1182/blood-2019-128295

Published: 2019

Journal Articles

Regulatory T Cell Adoptive Immunotherapy Promotes B Cell Immunity after Haploidentical Transplantation

Sara Piccinelli, Antonella Mancusi, PhD, Eni Hoxha, Loredana Ruggeri, MD, Franca Falzetti, MD, Alessandra Carotti, MD, Adelmo Terenzi, MD, Samanta Bonato, MD, Matteo Paradiso, MD, Tiziana Zei, Roberta Iacucci Ostini, Barbara Bigerna, Brunangelo Falini, MD PhD, Mauro Di Ianni, MD PhD, Massimo Fabrizio Martelli, MD, Andrea Velardi, MD, Antonio Pierini, MD PhD

Blood (2019) 134 (Supplement_1): 1917.

https://doi.org/10.1182/blood-2019-125715

Published: 2019

Journal Articles

Fast CMV and EBV Reactivations after Ruxolitinib for Graft-Versus-Host Disease Treatment

Dujardin Adèle, Pierre Morel, MD, Alexis Caulier, MD, Magalie Joris, MD, Amandine Charbonnier, MD, Berengere Gruson, MD, Marine Quint, Marie-Noëlle Lacassagne, Sandrine Castelain, MD PhD, Jean-Pierre Marolleau, MD PhD, Delphine Lebon, MD

Blood (2019) 134 (Supplement_1): 2007.

https://doi.org/10.1182/blood-2019-123283

Published: 2019

Journal Articles

Clinical Determinants of T-Cell Receptor Diversity after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

David Ritchie, MD PhD, Eric Wong, MD, Rachel Koldej, James Anton Kuzich, Piers Blombery, MBBS, Georgina L Ryland, Yamuna Kankanige, Jerick Guinto

Blood (2019) 134 (Supplement_1): 1997.

https://doi.org/10.1182/blood-2019-129308

Published: 2019

Journal Articles

Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Scott R. Solomon, MD, Melhem Solh, MD, Stacey Brown, CCRP, Katelin C Jackson, Xu Zhang, PhD, Lawrence E Morris, MD, H. Kent Holland, MD, Asad Bashey, MD PhD

Blood (2019) 134 (Supplement_1): 1998.

https://doi.org/10.1182/blood-2019-124354

Published: 2019

Journal Articles

NKG2C + CD57 + Natural Killer Cells May Play an Important Role in Maintaining Virus-Specific Immune Reconstitution Post-Allogeneic HSCT

Debora Basilio Basilio-Queiros, MSc, Susanne Luther, Arnold Ganser, MD, Eva M Weissinger, MD

Blood (2019) 134 (Supplement_1): 1939.

https://doi.org/10.1182/blood-2019-121914

Published: 2019

Journal Articles

Post-Transplant Cyclophosphamide for Gvhd Prophylaxis in Matched Unrelated Donor Transplantation Compared to ATG-Based Prophylaxis

Rebeca Bailén, MD, Mi Kwon, MD, Maria Jesus Pascual-Cascon, Anna Torrent, Christelle M Ferra, Jaime Sanz, MD PhD, Alberto Doblas-Marquez, Olga Benítez, MD, Jose Luis Piñana Sanchez, Gillen Oarbeascoa, MD, Nieves Dorado, MD, Muñoz Cristina, Carolina Martínez-Laperche, Javier Anguita, MD PhD, Ismael Buño, PhD, José Luis Díez-Martín, MD PhD

Blood (2019) 134 (Supplement_1): 3285.

https://doi.org/10.1182/blood-2019-124849

Published: 2019

Journal Articles

Subcutaneous Alemtuzumab Has Activity in Treatment-Naïve Patients with Acquired Aplastic Anemia

Ana Rita Da Fonseca, MD, Anita Hill, MD PhD, Patricia Eiko Yamakawa, MD, Iara Baldim Rabelo, MD PhD, Andre Domingues Pereira, MD, Vinicius Campos de Molla, MD, Matheus Vescovi Gonçalves, MD PhD, Morag Griffin, MD, Talha Munir, MD, Peter Hillmen, MD PhD, Louise Arnold, MD, Kathryn Riley, MD, Antonio M. Risitano, MD PhD, Phillip Scheinberg, MD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 2503.

https://doi.org/10.1182/blood-2019-130719

Published: 2019

Journal Articles

Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation

Hassan Awada, Reda Z. Mahfouz, MD PhD, Jibran Durrani, Ashwin Kishtagari, MBBS, Deepa Jagadeesh, MDMPH, Alan Lichtin, MD, Brian T. Hill, MD, Betty K. Hamilton, MD, Hetty E. Carraway, MD MBA, Navneet S. Majhail, MD MS, Ronald Sobecks, MD, Valeria Visconte, PhD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 1226.

https://doi.org/10.1182/blood-2019-130167

Published: 2019

Journal Articles

Differential Alemtuzumab Dosage Effects in T-Cell Deplete Allogeneic Haematopoietic Stem Cell Transplants for Myeloid Malignancies- King's College Hospital London Experience

Varun Mehra, MBBS,MRCP,FRCPath, Daniele Avenoso, MD, Ximena Cabrera Castellano, Adrian Choy, Stefani Widya, Mili Shah, FRCPath, Shafqat Inam, MD, Shreyans Gandhi, MBBS,MDDNB,MRCP,FRCPath,MPhil, Austin Kulasekararaj, MD MRCP, FRCPath, Francesco Dazzi, PhD, Ghulam J. Mufti, MBBS, FRCP, FRCPath, DM, Antonio Pagliuca, MBBS, MA, FRCP, FRCPath, Hugues De Lavallade, Victoria Potter, MBBS, BSc, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 4622.

https://doi.org/10.1182/blood-2019-131239

Published: 2019

Journal Articles

Comparative Analysis of Alpha-Beta T-Cell and B-Cell Depleted (abTCD) HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT) Versus Abtcd Haplo-HSCT with T-Cell Add-Back of Rivogenlecleucel Cell [Donor T Cells Transduced with the Inducible Caspase 9 (iC9) Gene Safety Switch] in Children with High-Risk Acute Leukemia (AL) in Remission

Annalisa Ruggeri, MD, Pietro Merli, MD, Mattia Algeri, MD, Marco Zecca, Franca Fagioli, MD, Giuseppina Li Pira, PhD, Valentina Bertaina, PhD, Arcangelo Prete, MD, Mauro Montanari, MD, Francesca Del Bufalo, MD, Luciana Vinti, MD, Daria Pagliara, MD PhD, Melissa Aldinger, PharmD, Kai Chan, Paul Woodard, Federica Galaverna, MD, Franco Locatelli, MD

Blood (2019) 134 (Supplement_1): 145.

https://doi.org/10.1182/blood-2019-125366

Published: 2019

Journal Articles

Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell Lymphomas

Sanjal Desai, MD, Christopher Melani, MD, Kieron Dunleavy, MD, Stefania Pittaluga, MD PhD, Mark A. Ahlman, MD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Mark Roschewski, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 4102.

https://doi.org/10.1182/blood-2019-127481

Published: 2019

Journal Articles

CMV-Seropositive Recipients Are at Higher Risk of CMV Reactivation and NRM after Haploidentical-SCT with PT-Cy

Jacopo Mariotti, Stefania Bramanti, Raynier Devillier, MD PhD, Barbara Sarina, Sabine Furst, MD, Angela Granata, MD, Valerio Maisano, MD, Thomas Pagliardini, MD, Chiara De Philippis, MD, Catherine Faucher, MD, Samia Harbi, MD, Christian Chabannon, MD PhD, Carmelo Carlo-Stella, MD, Reda Bouabdallah, Armando Santoro, Didier Blaise, MD PhD, Luca Castagna

Blood (2019) 134 (Supplement_1): 4484.

https://doi.org/10.1182/blood-2019-125101

Published: 2019

Journal Articles

Clonal Dynamics and Publicness of CMV-Specific TCR Repertoire after Allogeneic Stem Cell Transplantation

Blood (2019) 134 (Supplement_1): 4551.

https://doi.org/10.1182/blood-2019-122894

Published: 2019

Journal Articles

CMV-Specific T Cells Restricted By Shared and Donor, but Not By Host HLA Molecules Reconstitute in the First 180 Days after Allogeneic HSCT and Protect from CMV Reactivation: Results of a Prospective Observational Study

Maddalena Noviello, PhD, Elena Tassi, PhD, Pantaleo De Simone, MD, Francesca Serio, MD, Maria Teresa Lupo Stanghellini, Giacomo Oliveira, PhD, Sara Racca, Dr, Roee Dvir, MD, Lorenzo Lazzari, MD, Daniela Clerici, MD, Fabio Giglio, MD, Francesca Lorentino, MD, Consuelo Corti, MD, Massimo Bernardi, MD, Liselotte Brix, PhD, Fabio Ciceri, MD, Jacopo Peccatori, MD, Raffaella Greco, MD, Chiara Bonini, MD

Blood (2019) 134 (Supplement_1): 4536.

https://doi.org/10.1182/blood-2019-129779

Published: 2019

NARROW

Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation

How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation

Integrated Immune Signature Analyses Identifies Evolution of Distinct Immunoregulatory Cell Populations Which Control Alloreactivity after Allogeneic HSCT

Transcriptomic Analysis of CD4+ T Cell Dysfunction during Gvhd: Evidence for Profound Reprograming of T Cell Signaling during Acute Gvhd That Is Controlled during CD28:CD80/86 Costimulation Blockade with Abatacept

Haplo-Cord Transplantation with Anti-Thymocyte Globulin: Comparative Clinical Outcomes with or without Routine G-CSF Administration

Post-Transplant Cyclophosphamide in Allogeneic Bone Marrow Transplantation for the Treatment of Benign Hematologic Diseases

Regulatory T Cell Adoptive Immunotherapy Promotes B Cell Immunity after Haploidentical Transplantation

Fast CMV and EBV Reactivations after Ruxolitinib for Graft-Versus-Host Disease Treatment

Clinical Determinants of T-Cell Receptor Diversity after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

NKG2C + CD57 + Natural Killer Cells May Play an Important Role in Maintaining Virus-Specific Immune Reconstitution Post-Allogeneic HSCT

Post-Transplant Cyclophosphamide for Gvhd Prophylaxis in Matched Unrelated Donor Transplantation Compared to ATG-Based Prophylaxis

Subcutaneous Alemtuzumab Has Activity in Treatment-Naïve Patients with Acquired Aplastic Anemia

Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation

Differential Alemtuzumab Dosage Effects in T-Cell Deplete Allogeneic Haematopoietic Stem Cell Transplants for Myeloid Malignancies- King's College Hospital London Experience

Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell Lymphomas

CMV-Seropositive Recipients Are at Higher Risk of CMV Reactivation and NRM after Haploidentical-SCT with PT-Cy

Clonal Dynamics and Publicness of CMV-Specific TCR Repertoire after Allogeneic Stem Cell Transplantation

CMV-Specific T Cells Restricted By Shared and Donor, but Not By Host HLA Molecules Reconstitute in the First 180 Days after Allogeneic HSCT and Protect from CMV Reactivation: Results of a Prospective Observational Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only